Pharmaceuticals practice thrives

BR&C continues to grow its six-year-old pharmaceuticals practice.  Over that time the company has successfully executed projects in the realms of multiple sclerosis, psoriasis, Alzheimer’s, organ transplants, hemophilia and oncology.  Issues explored have included:

• Target indications for new drugs & treatments in clinical trials
• Clinical program goals & staffing requirements
• Status of existing clinical trials, including enrollment challenges & interim results
• Efficacy, side effects & drug interactions
• Comparisons with other drugs & likely positioning
• Formulation & administration
• Timing for next phases of development

We have also studied the changing nature of pharmaceutical sales forces given an operating climate that has grown much less friendly.  The work included how sales reps are judged for efficiency and effectiveness in the face of challenges posed by such developments as the AMA’s call for more distance between doctors and sales reps, medical institutions ratcheting back on access, the shift to managed care etc.  The research yielded keen insights on the evolution of metrics and incentives used to boost performance in this challenging new environment.

We helped execute a comparative analysis of current care and disease-management programs, including program structures and performance guarantees, ROI, pricing for different constituencies, predictive modeling, nurse staffing ratios and consumer-directed features.

In addition, BR&C was engaged to study the impact of the Medicare Modernization Act a full year before the law took effect, giving our client ample lead time to address new mandates and provide seamless service to retirees and employees about to retire.

BR&C foresees continued growth in pharma and biotech.  Managing Director Dave Giguere noted that the company specializes in partnering with its clients.  “BR&C’s function is to help clients in early identification of developments and patterns that may present exceptional opportunities or pose unacceptable risks,” he said.  In a world swamped with studies and claimed expertise, BR&C seeks to identify and isolate key data.  Added Giguere:  “The No. 1 thing that organizations want is early warning.  The biggest thing we hear from clients is: ‘I don’t want to be surprised.’”